Speciality pharmaceutical company Alliance Pharma has agreed to acquire exclusive marketing rights to medical anti-dandruff shampoo brand Nizoral in the Asia-Pacific region from Johnson & Johnson subsidiary Janssen Pharmaceutica, it announced on Tuesday, for a total consideration of £60m.
Alliance Pharma: Numis downgrades to add with a target price of 99p.
Specialist pharmaceutical firm Alliance Pharma on Thursday completed its UK regulatory application for its in-licensed drug Diclectin, a prescription treatment for nausea and vomiting during pregnancy.
Specialty pharmaceutical firm Alliance Pharma announced on Wednesday that non-executive director Thomas Casdagli will step down from the board with immediate effect.
Sage Group: JP Morgan downgrades to neutral with a target price of 670p.
AIM-listed Alliance Pharma said on Tuesday that it has agreed to sell its 60% interest in its non-core business, Unigreg, to joint venture partner Pacific Glory Development for £2.9m.
AIM-listed specialty pharmaceutical group Alliance Pharma has completed the acquisition of the worldwide rights to the Vamousse lice treatment range from Tyratech.
Specialty pharmaceutical group Alliance Pharma has agreed to buy the worldwide rights to pesticide-free lice treatment range Vamousse from TyraTech Inc for an initial consideration of $13m and a deferred contingent of up to $4.5m.
Speciality pharmaceutical group Alliance Pharma has acquired the rights to Ametop from global medical technology business Smith & Nephew for a total consideration of $7.5m.
Alliance Pharma reported on Tuesday that its "buy-and-build" strategy to evolve into a profitable, cash generative, speciality pharma business was bearing fruit, thanks to the sales performance of two international growth brands, Kelo-cote and MacuShield.
AIM-listed Alliance Pharma said on Tuesday that it performed well in the first half, with sales up 8% and trading in line with expectations.
AIM-listed Alliance Pharma has gained £5m in compensation from Sinclair Pharma in connection to a sales-shortfall of Kelo-stretch, a cream that treats stretch marks, which it bought in December 2015 as part of its acquisition of Sinclair's healthcare products business.
Specialty pharmaceutical company Alliance Pharma announced its pre-close trading update ahead of its preliminary results for the year to 31 December on Monday.
Alliance Pharma posted a jump in first-half profit and revenue as it benefited from the acquisition of the Sinclair Healthcare Products business last year.
Specialty pharmaceutical company Alliance Pharma said its sales more than doubled in the six months ended 30 June thanks to its acquisition of the Sinclair Healthcare Products business in December last year.
Alliance Pharma posted a rise in 2015 pre-tax profit as revenue grew following its acquisition of the Sinclair Healthcare Products division.
Speciality pharmaceutical company Alliance Pharma said it was trading in line with expectations, with sales of around £22.8m in in the six months ended June 30, up from £21.4m in the same period last year.
Specialty pharmaceutical company Alliance Pharma announced the appointment of Andrew Franklin as finance director with effect from 28 September 2015.
Pub operator Greene King has seen a slowdown in its sales for the fiscal year-to-date, but its recent purchase of rival Spirit Pub Company will pay off. In the 36 weeks since the start of the financial year like-for-like sales were ahead by 0.6%, a mediocre result, even if it was partially due to tough comparators.
Aggreko: Morgan Stanley ups target price from 1350p to 1375p, while leaving its underweight rating unaltered.